AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.

MSFT, AZN, and BLK lead Zacks' top stock picks, while TAYD and GEOS show resilience despite microcap market pressures.

Taken orally once daily and sold as Farxiga in certain markets, AZ’s Forxiga is a selective SGLT2 inhibitor that helps excess glucose pass out of the body in the urine. ... Tom Keith-Roach, president ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Investing.com – Shares of AstraZeneca (NASDAQ:AZN) (LON:AZN) dropped on Thursday after the company reported that other operating income is expected to "decrease substantially". This forecast ...